Abstract

The genotoxic agent cisplatin, used alone or in combination with radiation and/or other chemotherapeutic agents, is an important
first‐line chemotherapy for a broad range of cancers. The clinical utility of cisplatin is limited both by intrinsic and acquired
resistance and dose‐limiting normal tissue toxicity. That cisplatin shows little selectivity for tumor versus normal tissue
may be a critical factor limiting its value. To overcome the low therapeutic ratio of the free drug, macromolecular, liposomal,
and nanoparticle drug delivery systems have been explored toward leveraging the enhanced permeability and retention effect
and promoting delivery of cisplatin to tumors. Here, we survey recent advances in nanoparticle formulations of cisplatin,
focusing on agents that show promise in preclinical or clinical settings. WIREs Nanomed Nanobiotechnol 2016, 8:776–791. doi: 10.1002/wnan.1390

Images

(a) Cisplatin prodrug was attached onto the framework after synthesis. (Reprinted with permission from Ref . Copyright 2014 American Chemical Society). (b) Cisplatin prodrug was incorporated within NCPs through use of the prodrug as the building block. (Reprinted with permission from Ref . Copyright 2014 Nature Publishing Group)

Access to this WIREs title is by subscription only.

The latest WIREs articles in your inbox

In the Spotlight

started out in mechanical engineering and became interested in nanotechnology with his studies on nanomechanics and nanofluidics. His research work and involvement with setting up some of the premier nano centers and alliances in the world, bringing together universities, hospitals, and federal agencies, showcases interdisciplinarity at work.